Bigalke Boris, Stellos Konstantinos, Weig Hans-Jörg, Geisler Tobias, Seizer Peter, Kremmer Elisabeth, Pötz Oliver, Joos Thomas, May Andreas E, Lindemann Stephan, Gawaz Meinrad
Medizinische Klinik III, Klinik für Kardiologie und Kreislauferkrankungen, Eberhard-Karls-Universität Tübingen, Tübingen, Germany.
Basic Res Cardiol. 2009 May;104(3):352-7. doi: 10.1007/s00395-009-0779-7. Epub 2009 Feb 3.
The platelet collagen receptor glycoprotein VI (GPVI) mediates platelet adhesion to subendothelial matrix and thrombus formation in acute coronary syndrome (ACS). This study examined patients with both ACS and stable coronary artery disease (CAD), which presented with atrial fibrillation (AF) and sinus rhythm (SR).
We evaluated 992 patients with acute or stable CAD, and determined platelet surface expression of GPVI using flow cytometry. Seventy-eight patients presented with nonvalvular persistent AF. After 1:1 propensity score matching 156 matched cases with 78 pairs were obtained. Patients with AF and ACS showed a significantly decreased GPVI expression compared to patients with ACS and SR, whereas patients with stable angina pectoris (SA) presented with low level activation and no significant difference between SR and AF [mean fluorescence intensity (MFI) for ACS (SR Vs. AF): 20 +/- 6.3 Vs. 17.7 +/- 4.4; P = 0.023; SA (SR Vs. AF): 18.8 +/- 9.4 Vs. 18.1 +/- 6.1; P = 0.649]. In contrast, soluble GPVI was increased in ACS and AF accordingly [plasma GPVI (ng/ml) for ACS (SR Vs. AF): 1.4 +/- 0.8 Vs. 1.9 +/- 1.1; P = 0.038; SA (SR Vs. AF): 0.9 +/- 0.4 Vs. 1.1 +/- 0.5; P = 0.127].
Platelet GPVI surface expression is decreased in patients with AF and ACS compared to patients with SR and ACS. Nonvalvular AF is related to indices of chronic platelet activation and might be responsible for a down-regulation of GPVI receptor density on platelets, while soluble GPVI was increased in ACS and AF accordingly.
血小板胶原受体糖蛋白VI(GPVI)介导血小板与急性冠状动脉综合征(ACS)患者的内皮下基质黏附及血栓形成。本研究对同时患有ACS和稳定型冠状动脉疾病(CAD)且伴有心房颤动(AF)和窦性心律(SR)的患者进行了检查。
我们评估了992例急性或稳定型CAD患者,并使用流式细胞术测定血小板表面GPVI的表达。78例患者出现非瓣膜性持续性AF。经过1:1倾向评分匹配,获得了156例匹配病例,共78对。与患有ACS和SR的患者相比,患有AF和ACS的患者GPVI表达显著降低,而患有稳定型心绞痛(SA)的患者表现为低水平激活,SR和AF之间无显著差异[ACS的平均荧光强度(MFI)(SR与AF):20±6.3对17.7±4.4;P = 0.023;SA(SR与AF):18.8±9.4对18.1±6.1;P = 0.649]。相反,ACS和AF患者的可溶性GPVI相应增加[ACS的血浆GPVI(ng/ml)(SR与AF):1.4±0.8对1.9±1.1;P = 0.038;SA(SR与AF):0.9±0.4对1.1±0.5;P = 0.127]。
与患有SR和ACS的患者相比,患有AF和ACS的患者血小板GPVI表面表达降低。非瓣膜性AF与慢性血小板激活指标相关,可能是血小板上GPVI受体密度下调的原因,而ACS和AF患者的可溶性GPVI相应增加。